The conventional venture capital model, though effective for biotech, poses distinct challenges for early-stage medtech companies. Unlike therapeutics, medtech often lacks shorter-term exit opportunities, such as mergers and acquisitions following FDA Phase 2 success. Furthermore, the potential for substantial returns upon FDA Phase 3 success in therapeutics can make them a more appealing investment. Consequently, a funding gap emerges, where innovative neurotechnology companies or projects with promising scientific foundations but limited clinical evidence face difficulties in securing the capital needed for advancement.
Nexus NeuroTech's Incubator Program aims to address this gap by employing a hybrid approach, combining aspects of both foundry/venture studio and pre-seed/seed investment models. This will enable us to support and invest in potentially transformative technologies that may not yet be ready for traditional venture capital.
In this vertical, we create new companies based on promising intellectual property from our network of inventors and universities. These ventures will focus on advancing technologies aligned with Nexus NeuroTech’s strategic focus areas. The incubator will offer the necessary resources and expertise to drive these innovations through technical and clinical development, positioning them for pivotal trials and successful commercialization.
In this vertical, we invest in pre-seed and seed-stage opportunities, supporting university spin-outs and startups that are developing neurotechnology solutions. These investments will align with Nexus NeuroTech’s strategic focus areas.
The Nexus NeuroTech Incubator Program focuses on investing in technologies targeting Parkinson’s disease, autism spectrum disorder, and bipolar disorder, along with cross-cutting clinical areas such as seizures (common in autism spectrum disorder and elevated risk in Parkinson’s disease), cognitive dysfunction (common in Parkinson’s disease, autism spectrum disorder, and bipolar disorder), and mood disorders (common across autism spectrum disorder, Parkinson’s disease, and bipolar disorder) with:
Nexus NeuroTech is part of a broader ecosystem, which includes a number of leading organizations dedicated to advancing research and care for brain disorders. The incubator program will leverage the resources and expertise of our ecosystem to provide portfolio companies with access to:
Beyond capital, we offer a wide range of resources and support to help our portfolio companies succeed.
